Precision BioSciences on Tuesday reported a loss of $26 million in its third quarter, but its CEO stressed positive news in patent victories and research progress. Here’s what happened.
Read More
Two Durham-based life science firms – Precision BioSciences and Chimerix – reported losses this week. Here’s the latest.
Read More
Precision Biosciences’ two-year collaboration with Gilead Sciences to develop new therapies to cure hepatitis B will end in September. Here’s what’s going on.
Read More
News from across North Carolina includes headliness from RedHill BioPharma, Qorvo, TransEnterix, FM:Systems, Precision BioSciences, BDSI; and Form Technologies.
Read More
Precision BioSciences, a Durham-based genome editing company, has reached two regulatory milestones for its potential therapy against multiple myeloma, a chronic cancer of white blood cells.
Read More
He has previously served as the firm’s chief development officer since 2017.
Read More
Precision BioSciences, a genome-editing company based in Durham, has received authorization from the U.S. Food and Drug Administration to advance its second genome-edited cancer therapy to clinical trials.
Read More
Precision BioSciences, a genome-editing company based in Durham, announced today the opening of its highly prized production facility for in-house manufacturing of its unique technologies.
Read More
Precision BioSciences Inc. saw its stock increase by 9 percent on Thursday, its first day as a publicly traded company, after raising $126.4 million in its initial public offering.
Read More
